{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T07:33:18Z","timestamp":1774078398993,"version":"3.50.1"},"reference-count":55,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,2,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The development of therapeutic concepts in pulmonary hypertension (PH) is intimately linked with the unraveling of pathogenetic sequelae. This perspective highlights advances in our understanding of the regulation of vasomotion and vascular remodeling that have led to \u201creverse-remodeling\u201d and regenerative strategies as novel treatment concepts. Progress has been made in understanding redox-dependent signaling; inflammatory sequelae; and transcription factor, ion channel, and metabolic abnormalities, as well as growth factor\u2013dependent hyperproliferation that underlies PH. We are, however, far from understanding the molecular pathways that differentially drive the various vascular phenotypes (intimal thickening, media hypertrophy, adventitial thickening, plexiform lesions, vascular pruning) in this disease. Antiproliferative strategies, transcription factor\u2013based therapies, inflammation\/immune cell\u2013focused approaches, and epigenetic modulation\u2013based therapies are all novel treatment concepts for PH. The proangiogenic potential of genetically engineered mesenchymal stem cells and endothelial progenitor cells has been explored as a regenerative strategy. The progress that has been made in identifying important cellular and molecular mechanisms and applying this knowledge to novel therapies is largely restricted to group 1 PH. However, understanding the molecular sequelae underlying PH in groups 2 through 5 PH is also urgently needed.<\/jats:p>","DOI":"10.1164\/rccm.201308-1543pp","type":"journal-article","created":{"date-parts":[[2014,2,14]],"date-time":"2014-02-14T21:04:44Z","timestamp":1392411884000},"page":"394-400","source":"Crossref","is-referenced-by-count":75,"title":["Novel and Emerging Therapies for Pulmonary Hypertension"],"prefix":"10.1093","volume":"189","author":[{"given":"Soni Savai","family":"Pullamsetti","sequence":"first","affiliation":[{"name":"Max-Planck-Institute for Heart and Lung Research, Department of Lung Development and Remodeling, member of the German Center for Lung Research (DZL), Bad Nauheim, Germany; and"},{"name":"Universities of Giessen and Marburg Lung Center (UGMLC), member of the German Center for Lung Research (DZL), Justus-Liebig University, Giessen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralph","family":"Schermuly","sequence":"additional","affiliation":[{"name":"Universities of Giessen and Marburg Lung Center (UGMLC), member of the German Center for Lung Research (DZL), Justus-Liebig University, Giessen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ardeschir","family":"Ghofrani","sequence":"additional","affiliation":[{"name":"Universities of Giessen and Marburg Lung Center (UGMLC), member of the German Center for Lung Research (DZL), Justus-Liebig University, Giessen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norbert","family":"Weissmann","sequence":"additional","affiliation":[{"name":"Universities of Giessen and Marburg Lung Center (UGMLC), member of the German Center for Lung Research (DZL), Justus-Liebig University, Giessen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Friedrich","family":"Grimminger","sequence":"additional","affiliation":[{"name":"Universities of Giessen and Marburg Lung Center (UGMLC), member of the German Center for Lung Research (DZL), Justus-Liebig University, Giessen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Werner","family":"Seeger","sequence":"additional","affiliation":[{"name":"Max-Planck-Institute for Heart and Lung Research, Department of Lung Development and Remodeling, member of the German Center for Lung Research (DZL), Bad Nauheim, Germany; and"},{"name":"Universities of Giessen and Marburg Lung Center (UGMLC), member of the German Center for Lung Research (DZL), Justus-Liebig University, Giessen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2014,2,15]]},"reference":[{"key":"2026032100344828300_bib1","doi-asserted-by":"crossref","first-page":"4306","DOI":"10.1172\/JCI60658","article-title":"Molecular pathogenesis of pulmonary arterial hypertension","volume":"122","author":"Rabinovitch","year":"2012","journal-title":"J Clin Invest"},{"key":"2026032100344828300_bib2","doi-asserted-by":"crossref","first-page":"128","DOI":"10.4103\/2045-8932.109951","article-title":"Mechanics and mechanisms of pulmonary hypertension-conference summary and translational perspectives","volume":"3","author":"Seeger","year":"2013","journal-title":"Pulm Circ"},{"key":"2026032100344828300_bib3","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1183\/09031936.00137511","article-title":"Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension","volume":"40","author":"Simonneau","year":"2012","journal-title":"Eur Respir J"},{"key":"2026032100344828300_bib4","doi-asserted-by":"crossref","first-page":"e47662","DOI":"10.1371\/journal.pone.0047662","article-title":"Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells","volume":"7","author":"Gatfield","year":"2012","journal-title":"PLoS ONE"},{"key":"2026032100344828300_bib5","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1213917","article-title":"Macitentan and morbidity and mortality in pulmonary arterial hypertension","volume":"369","author":"Pulido","year":"2013","journal-title":"N Engl J Med"},{"key":"2026032100344828300_bib6","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1161\/CIRCULATIONAHA.105.581405","article-title":"Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling","volume":"113","author":"Dumitrascu","year":"2006","journal-title":"Circulation"},{"key":"2026032100344828300_bib7","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1209655","article-title":"Riociguat for the treatment of pulmonary arterial hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N Engl J Med"},{"key":"2026032100344828300_bib8","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1209657","article-title":"Riociguat for the treatment of chronic thromboembolic pulmonary hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N Engl J Med"},{"key":"2026032100344828300_bib9","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.freeradbiomed.2010.04.030","article-title":"NADPH oxidases in cardiovascular disease","volume":"49","author":"Brandes","year":"2010","journal-title":"Free Radic Biol Med"},{"key":"2026032100344828300_bib10","doi-asserted-by":"crossref","first-page":"L2","DOI":"10.1152\/ajplung.00135.2005","article-title":"Hypoxic pulmonary hypertension: role of superoxide and NADPH oxidase (gp91phox)","volume":"290","author":"Liu","year":"2006","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"2026032100344828300_bib11","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1161\/CIRCRESAHA.107.148015","article-title":"Hypoxia-dependent regulation of nonphagocytic NADPH oxidase subunit NOX4 in the pulmonary vasculature","volume":"101","author":"Mittal","year":"2007","journal-title":"Circ Res"},{"key":"2026032100344828300_bib12","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.2353\/ajpath.2010.090832","article-title":"Hypoxia inducible-factor1alpha regulates the metabolic shift of pulmonary hypertensive endothelial cells","volume":"176","author":"Fijalkowska","year":"2010","journal-title":"Am J Pathol"},{"key":"2026032100344828300_bib13","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1080\/10739680600930222","article-title":"The role of k+ channels in determining pulmonary vascular tone, oxygen sensing, cell proliferation, and apoptosis: implications in hypoxic pulmonary vasoconstriction and pulmonary arterial hypertension","volume":"13","author":"Moudgil","year":"2006","journal-title":"Microcirculation"},{"key":"2026032100344828300_bib14","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1161\/hc0202.101974","article-title":"Dichloroacetate, a metabolic modulator, prevents and reverses chronic hypoxic pulmonary hypertension in rats: role of increased expression and activity of voltage-gated potassium channels","volume":"105","author":"Michelakis","year":"2002","journal-title":"Circulation"},{"key":"2026032100344828300_bib15","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S0140-6736(05)78495-6","article-title":"Attenuated K+ channel gene transcription in primary pulmonary hypertension","volume":"351","author":"Yuan","year":"1998","journal-title":"Lancet"},{"key":"2026032100344828300_bib16","doi-asserted-by":"crossref","first-page":"H570","DOI":"10.1152\/ajpheart.01324.2007","article-title":"Mitochondrial metabolism, redox signaling, and fusion: a mitochondria-ROS-HIF-1alpha-Kv1.5 O2-sensing pathway at the intersection of pulmonary hypertension and cancer","volume":"294","author":"Archer","year":"2008","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2026032100344828300_bib17","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/j.lfs.2004.03.031","article-title":"Effects of iptakalim hydrochloride, a novel KATP channel opener, on pulmonary vascular remodeling in hypoxic rats","volume":"75","author":"Xie","year":"2004","journal-title":"Life Sci"},{"key":"2026032100344828300_bib18","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1161\/CIRCULATIONAHA.108.782458","article-title":"A functional single-nucleotide polymorphism in the TRPC6 gene promoter associated with idiopathic pulmonary arterial hypertension","volume":"119","author":"Yu","year":"2009","journal-title":"Circulation"},{"key":"2026032100344828300_bib19","doi-asserted-by":"crossref","first-page":"19093","DOI":"10.1073\/pnas.0606728103","article-title":"Classical transient receptor potential channel 6 (TRPC6) is essential for hypoxic pulmonary vasoconstriction and alveolar gas exchange","volume":"103","author":"Weissmann","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026032100344828300_bib20","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1378\/chest.11-1460","article-title":"An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry","volume":"142","author":"Benza","year":"2012","journal-title":"Chest"},{"key":"2026032100344828300_bib21","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nrcardio.2011.87","article-title":"Mechanisms of disease: pulmonary arterial hypertension","volume":"8","author":"Schermuly","year":"2011","journal-title":"Nat Rev Cardiol"},{"key":"2026032100344828300_bib22","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1172\/JCI24838","article-title":"Reversal of experimental pulmonary hypertension by PDGF inhibition","volume":"115","author":"Schermuly","year":"2005","journal-title":"J Clin Invest"},{"key":"2026032100344828300_bib23","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1161\/CIRCULATIONAHA.112.000765","article-title":"Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study","volume":"127","author":"Hoeper","year":"2013","journal-title":"Circulation"},{"key":"2026032100344828300_bib24","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1161\/ATVBAHA.112.248500","article-title":"Role of Src tyrosine kinases in experimental pulmonary hypertension","volume":"32","author":"Pullamsetti","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026032100344828300_bib25","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1161\/CIRCULATIONAHA.111.079921","article-title":"Pulmonary arterial hypertension in patients treated by dasatinib","volume":"125","author":"Montani","year":"2012","journal-title":"Circulation"},{"key":"2026032100344828300_bib26","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1164\/rccm.200811-1682OC","article-title":"Role of epidermal growth factor inhibition in experimental pulmonary hypertension","volume":"181","author":"Dahal","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032100344828300_bib27","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1172\/JCI35070","article-title":"Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents","volume":"119","author":"Izikki","year":"2009","journal-title":"J Clin Invest"},{"key":"2026032100344828300_bib28","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1161\/CIRCULATIONAHA.108.779751","article-title":"Combined tyrosine and serine\/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling","volume":"118","author":"Klein","year":"2008","journal-title":"Circulation"},{"key":"2026032100344828300_bib29","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/j.ijcard.2012.06.129","article-title":"Effects of multikinase inhibitors on pressure overload-induced right ventricular remodeling","volume":"167","author":"Kojonazarov","year":"2013","journal-title":"Int J Cardiol"},{"key":"2026032100344828300_bib30","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/clpt.2009.217","article-title":"A dosing\/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension","volume":"87","author":"Gomberg-Maitland","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"2026032100344828300_bib31","doi-asserted-by":"crossref","first-page":"11418","DOI":"10.1073\/pnas.0610467104","article-title":"The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted","volume":"104","author":"Bonnet","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026032100344828300_bib32","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1172\/JCI32503","article-title":"An antiproliferative BMP-2\/PPARgamma\/apoE axis in human and murine SMCs and its role in pulmonary hypertension","volume":"118","author":"Hansmann","year":"2008","journal-title":"J Clin Invest"},{"key":"2026032100344828300_bib33","doi-asserted-by":"crossref","first-page":"L885","DOI":"10.1152\/ajplung.00258.2006","article-title":"Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling","volume":"292","author":"Crossno","year":"2007","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"2026032100344828300_bib34","doi-asserted-by":"crossref","first-page":"e18883","DOI":"10.1371\/journal.pone.0018883","article-title":"Glycogen synthase kinase 3beta contributes to proliferation of arterial smooth muscle cells in pulmonary hypertension","volume":"6","author":"Sklepkiewicz","year":"2011","journal-title":"PLoS ONE"},{"key":"2026032100344828300_bib35","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1083\/jcb.200806049","article-title":"Bone morphogenetic protein 2 induces pulmonary angiogenesis via Wnt-beta-catenin and Wnt-RhoA-Rac1 pathways","volume":"184","author":"de Jesus Perez","year":"2009","journal-title":"J Cell Biol"},{"key":"2026032100344828300_bib36","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1172\/JCI38079","article-title":"Wnt signaling regulates smooth muscle precursor development in the mouse lung via a tenascin C\/PDGFR pathway","volume":"119","author":"Cohen","year":"2009","journal-title":"J Clin Invest"},{"key":"2026032100344828300_bib37","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1038\/nm.2021","article-title":"Notch3 signaling promotes the development of pulmonary arterial hypertension","volume":"15","author":"Li","year":"2009","journal-title":"Nat Med"},{"key":"2026032100344828300_bib38","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1164\/rccm.201202-0335OC","article-title":"Immune and inflammatory cell involvement in the pathology of idiopathic pulmonary arterial hypertension","volume":"186","author":"Savai","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032100344828300_bib39","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1378\/chest.11-0793","article-title":"Inflammation in pulmonary arterial hypertension","volume":"141","author":"Price","year":"2012","journal-title":"Chest"},{"key":"2026032100344828300_bib40","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1161\/CIRCRESAHA.110.236927","article-title":"Regulatory T cells limit vascular endothelial injury and prevent pulmonary hypertension","volume":"109","author":"Tamosiuniene","year":"2011","journal-title":"Circ Res"},{"key":"2026032100344828300_bib41","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1165\/rcmb.2012-0077OC","article-title":"Severe pulmonary arterial hypertension induced by SU5416 and ovalbumin immunization","volume":"47","author":"Mizuno","year":"2012","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2026032100344828300_bib42","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1084\/jem.20101812","article-title":"Role for miR-204 in human pulmonary arterial hypertension","volume":"208","author":"Courboulin","year":"2011","journal-title":"J Exp Med"},{"key":"2026032100344828300_bib43","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1161\/CIRCRESAHA.112.267591","article-title":"A role for miR-145 in pulmonary arterial hypertension: evidence from mouse models and patient samples","volume":"111","author":"Caruso","year":"2012","journal-title":"Circ Res"},{"key":"2026032100344828300_bib44","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1164\/rccm.201106-1093OC","article-title":"Inhibition of microRNA-17 improves lung and heart function in experimental pulmonary hypertension","volume":"185","author":"Pullamsetti","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032100344828300_bib45","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1161\/CIRCULATIONAHA.112.103176","article-title":"Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid","volume":"126","author":"Zhao","year":"2012","journal-title":"Circulation"},{"key":"2026032100344828300_bib46","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1161\/CIRCRESAHA.111.258426","article-title":"Selective class I histone deacetylase inhibition suppresses hypoxia-induced cardiopulmonary remodeling through an antiproliferative mechanism","volume":"110","author":"Cavasin","year":"2012","journal-title":"Circ Res"},{"key":"2026032100344828300_bib47","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1164\/rccm.201007-1106OC","article-title":"Suppression of histone deacetylases worsens right ventricular dysfunction after pulmonary artery banding in rats","volume":"183","author":"Bogaard","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032100344828300_bib48","doi-asserted-by":"crossref","first-page":"347","DOI":"10.4103\/2045-8932.87300","article-title":"Epigenetic mechanisms of pulmonary hypertension","volume":"1","author":"Kim","year":"2011","journal-title":"Pulm Circ"},{"key":"2026032100344828300_bib49","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1161\/01.CIR.0000012754.72951.3D","article-title":"Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor","volume":"105","author":"Atkinson","year":"2002","journal-title":"Circulation"},{"key":"2026032100344828300_bib50","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1172\/JCI65592","article-title":"FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension","volume":"123","author":"Spiekerkoetter","year":"2013","journal-title":"J Clin Invest"},{"key":"2026032100344828300_bib51","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1513\/pats.201105-035MW","article-title":"Cell-based therapies for lung vascular diseases: lessons for the future","volume":"8","author":"Stewart","year":"2011","journal-title":"Proc Am Thorac Soc"},{"key":"2026032100344828300_bib52","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/j.jacc.2006.12.037","article-title":"Transplantation of autologous endothelial progenitor cells may be beneficial in patients with idiopathic pulmonary arterial hypertension: a pilot randomized controlled trial","volume":"49","author":"Wang","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"2026032100344828300_bib53","doi-asserted-by":"crossref","first-page":"H1120","DOI":"10.1152\/ajpheart.00173.2006","article-title":"Intratracheal mesenchymal stem cell administration attenuates monocrotaline-induced pulmonary hypertension and endothelial dysfunction","volume":"292","author":"Baber","year":"2007","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2026032100344828300_bib54","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1161\/CIRCULATIONAHA.110.941484","article-title":"cAMP phosphodiesterase inhibitors increases nitric oxide production by modulating dimethylarginine dimethylaminohydrolases","volume":"123","author":"Pullamsetti","year":"2011","journal-title":"Circulation"},{"key":"2026032100344828300_bib55","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1172\/JCI43382","article-title":"Disruption of PPAR\u03b3\/\u03b2-catenin-mediated regulation of apelin impairs BMP-induced mouse and human pulmonary arterial EC survival","volume":"121","author":"Alastalo","year":"2011","journal-title":"J Clin Invest"}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/189\/4\/394\/67291080\/ajrccm_189_4_394.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/189\/4\/394\/67291080\/ajrccm_189_4_394.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T04:35:47Z","timestamp":1774067747000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/189\/4\/394\/8506149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":55,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2014,2,15]]},"published-print":{"date-parts":[[2014,2,15]]}},"URL":"https:\/\/doi.org\/10.1164\/rccm.201308-1543pp","relation":{},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2014,2]]},"published":{"date-parts":[[2014,2]]}}}